Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, with nearly half of all patients diagnosed at an advanced stage. Immune checkpoint inhibitors (ICIs) harness the host immune system to combat malign...
Saved in:
| Main Authors: | Emily Wolf, Guilherme Sacchi de Camargo Correia, Shenduo Li, Yujie Zhao, Rami Manochakian, Yanyan Lou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/2/128 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01) -
Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches
by: Sherif A. El-Kafrawy, et al.
Published: (2025-06-01) -
Current and future immunotherapy for breast cancer
by: Natalie K. Heater, et al.
Published: (2024-12-01) -
Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01) -
Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review
by: Torchia A, et al.
Published: (2025-04-01)